Site Search

This report is a summary of an IMI-hosted event called IMI Impact on diabetes, part of a series of events intended to showcase the successes of projects launched since IMI was launched in 2008.

What RESOLUTE found as part of a recent experiment drives home their point about SLCs as under-valued drug targets. They hope their tools will help fix this.

Before the establishment of EBiSC, sharing disease-specific stem cell lines for research and development was fraught with challenges.

VHFMoDRAD have made progress in understanding how different antibodies can be useful for diagnosing and detecting RVF virus in animal and insect tissues.

Eu2P have offered a growing suite of certified drug-safety education courses since 2009, with renewed interest in the discipline spurred by COVID19. They are now expanding beyond the EU.

PRISM is in talks with the EMA on the use of data from smartphones and wearables as biomarkers of social functioning in neuropsychiatric disorders.

New IMI project REsolution focuses on solute carriers, a large family of proteins that is not well studied despite being implicated in a number of diseases.

IMI is a catalyst, and our research has been a launch pad for vital research infrastructures that will drive innovation long after projects have finished

Building on ground-breaking results from IMI diabetes projects, scientists are now working on a software tool that would identify what subtype of diabetes a patient has and suggest which treatment would work best for them.